Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) (AMPLITUDE-L)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03713684 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 22, 2018
Last Update Posted : November 18, 2020
|
Sponsor:
Sanofi
Information provided by (Responsible Party):
Sanofi
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Primary Objective:
To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with basal insulin alone or in combination with oral antidiabetic drugs (OADs).
Secondary Objectives:
- To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on glycemic control.
- To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on body weight.
- To evaluate the safety of once weekly injection of efpeglenatide.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 2 Diabetes Mellitus | Drug: Efpeglenatide SAR439977 Drug: Placebo Drug: Insulin glargine | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 400 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) |
| Actual Study Start Date : | November 9, 2018 |
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Type 2 diabetes
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Efpeglenatide low dose
Efpeglenatide low dose (prefilled syringe) administered once weekly for 56 weeks
|
Drug: Efpeglenatide SAR439977
Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Insulin glargine Pharmaceutical form: solution for injection Route of administration: subcutaneous |
|
Experimental: Efpeglenatide middle dose
Efpeglenatide middle dose (prefilled syringe) administered once weekly for 56 weeks
|
Drug: Efpeglenatide SAR439977
Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Insulin glargine Pharmaceutical form: solution for injection Route of administration: subcutaneous |
|
Experimental: Efpeglenatide high dose
Efpeglenatide high dose (prefilled syringe) administered once weekly for 56 weeks
|
Drug: Efpeglenatide SAR439977
Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Insulin glargine Pharmaceutical form: solution for injection Route of administration: subcutaneous |
|
Placebo Comparator: Placebo
Matching placebo (prefilled syringe) administered once weekly for 56 weeks
|
Drug: Placebo
Pharmaceutical form: solution for injection Route of administration: subcutaneous Drug: Insulin glargine Pharmaceutical form: solution for injection Route of administration: subcutaneous |
Primary Outcome Measures :
- Change in glycated hemoglobin (HbA1c) [ Time Frame: Baseline to Week 30 ]Change from Baseline to Week 30 in HbA1c
Secondary Outcome Measures :
- Change in HbA1c [ Time Frame: Baseline to Week 56 ]Change from Baseline to Week 56 in HbA1c
- Change in fasting plasma glucose (FPG) [ Time Frame: Baseline to Week 30 ]Change from Baseline to Week 30 in FPG
- Participants with HbA1c <7.0% [ Time Frame: Baseline to Week 30 ]Number of participants with HbA1c < 7.0% at Week 30
- Change in body weight [ Time Frame: Baseline to Week 30 and Week 56 ]Change from Baseline to Week 30 and Week 56 in body weight
- Hypoglycemic participants [ Time Frame: Baseline to Week 56 ]Number of participants with at least one hypoglycemic event during treatment period
- Hypoglycemic events [ Time Frame: Baseline to Week 56 ]Number of hypoglycemic events per participant-year during treatment period
- Adverse events (AEs) [ Time Frame: Baseline to Week 30 and Week 56 ]Number of participants with AEs
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Participant must be ≥18 years of age at the time of signing the informed consent.
- Participants with type 2 diabetes mellitus (T2DM).
- Diabetes diagnosed at least 1 year before screening.
- Participants on basal insulin regimen alone or in combination with oral antidiabetic drugs (OADs) for at least 6 months prior to screening.
- Glycated hemoglobin (HbA1c) between 7.0% and 10.0% (inclusive) measured by the central laboratory at screening.
Exclusion criteria:
- History of severe hypoglycemia requiring emergency room admission or hospitalization within 3 months prior to screening.
- Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery.
- Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease requiring medical treatment within 6 months prior to screening.
- History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy.
- Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).
- Body weight change of ≥5 kg within the last 3 months prior to screening.
- Systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at randomization.
- End-stage renal disease as defined by estimated glomerular filtration rate (eGFR, by Modification of Diet in Renal Disease [MDRD]) of <15 mL/min/1.73 m2.
-
Laboratory findings at the screening Visit:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 x upper limit of normal (ULN) or total bilirubin >1.5 x ULN (except in case of documented Gilbert's syndrome);
- Amylase and/or lipase: >3 x ULN;
- Calcitonin ≥5.9 pmol/L (20 pg/mL).
- Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to screening, or planned during study period.
- Pregnant (confirmed by serum pregnancy test at screening) or breast-feeding women.
- Women of childbearing potential (WOCBP) not willing to use highly effective method(s) of birth control or who are unwilling to be tested for pregnancy during the study period and for at least 5 weeks after the last dose of study intervention.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03713684
Locations
Show 48 study locations
Sponsors and Collaborators
Sanofi
Investigators
| Study Director: | Clinical Sciences & Operations | Sanofi |
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT03713684 |
| Other Study ID Numbers: |
EFC14893 U1111-1189-5009 ( Other Identifier: UTN ) |
| First Posted: | October 22, 2018 Key Record Dates |
| Last Update Posted: | November 18, 2020 |
| Last Verified: | November 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/ |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Insulin Glargine Hypoglycemic Agents Physiological Effects of Drugs |